The MHC class II transactivator modulates seeded alpha-synuclein pathology and dopaminergic neurodegeneration in an in vivo rat model of Parkinson's disease.
Jimenez-Ferrer I, Bäckström F, Dueñas-Rey A, Jewett M, Boza-Serrano A, Luk KC, Deierborg T, Swanberg M. Brain Behav Immun. 2021 Jan; 91:369-382. Epub 2020 Oct 22.